BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
March 25, 2011
View Archived Issues
New protein kinase inhibitors patented by Cylene Pharmaceuticals
Read More
Novel series of vasopressin receptor antagonists presented by Bayer
Read More
Karus Therapeutics presents new PI3K inhibitors
Read More
Arisaph Pharmaceuticals receives FDA IND approval for first-in-human study of ARI-3037-MO
Read More
Novel deuterated voltage-gated calcium channel blockers patented by Merck & Co.
Read More
Levels of Kit ligand in the serum described as possible biomarker for AIU
Read More
Results from phase I/II trial of MDV-3100 in CRPC reveal long-term efficacy
Read More
Two phase III studies demonstrate the efficacy of mirabegron in overactive bladder
Read More
Phase III study results detailed for abiraterone acetate in metastatic CRPC
Read More
Abbott synthesizes new lysophospholipid receptor agonists for cognition disorders
Read More
Novel B-raf kinase inhibitors presented by Novartis
Read More
GSK patents novel orexin receptor antagonists for sleep disorders
Read More
Omeros' phase IIb study of OMS-302 meets coprimary endpoints in cataract surgery
Read More
Genesis Biopharma develops active immunotherapy platform for cancer
Read More
Nordion cleared to begin two phase III TheraSphere trials in cancer
Read More
Merck & Co. receives FDA approval for expanded age indication for Zostavax
Read More
Oncolytics Biotech completes enrollment in phase II Reolysin trial in head and neck cancers
Read More
Targacept's TC-5619 misses primary endpoint in phase II proof-of-concept trial for ADHD
Read More
Stemedica treats first subject in phase I/II study of ischemic allogeneic mesenchymal stem cells
Read More
Vectura's VR-496 shows anti-inflammatory activity in phase II cystic fibrosis trial
Read More
CHMP recommends new indication for Herceptin in early breast cancer
Read More
Rockwell Medical begins enrollment in pivotal phase III study of continuous iron therapy SFP
Read More
Oramed Pharmaceuticals completes toxicity study for oral insulin capsule
Read More
Pozen reports positive results for PA-32540 in healthy subjects
Read More
FDA approves Gel-One for pain associated with osteoarthritis of the knee
Read More
Cilag to market Pozen's antimigraine treatment MT-400 in parts of South America
Read More